Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PER2 | O15055 | 15/20 | 1.00 |
| ▸ | CRY1 | Q16526 | 14/20 | 1.00 |
| ▸ | CRY2 | Q49AN0 | 14/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | TSHR | P16473 | 1/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 3/20 | 0.69 |
| ▸ | GAA | P10253 | 1/20 | 0.69 |
| ▸ | HTT | P42858 | 1/20 | 0.69 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15383953 | 0.84 | PER2 (1.00) | PER2CRY1CRY2ALDH1A1LMNA | |
| SCHEMBL15383949 | 0.83 | CRY1 (1.00) | PER2CRY1CRY2ALDH1A1LMNA | |
| SCHEMBL15383952 | 0.83 | PER2 (1.00) | PER2CRY1CRY2ALDH1A1LMNA | |
| SCHEMBL15383956 | 0.82 | CRY1 (1.00) | PER2CRY1CRY2ALDH1A1LMNA | |
| SCHEMBL15383965 | 0.81 | CRY1 (1.00) | PER2CRY1CRY2ALDH1A1 | |
| SCHEMBL15383964 | 0.81 | CRY1 (1.00) | PER2CRY1CRY2ALDH1A1 | |
| SCHEMBL15383948 | 0.80 | CRY1 (1.00) | PER2CRY1CRY2ALDH1A1LMNA | |
| SCHEMBL15383950 | 0.80 | CRY1 (0.83) | PER2CRY1CRY2ALDH1A1LMNA | |
| SCHEMBL15383954 | 0.80 | CRY1 (1.00) | PER2CRY1CRY2ALDH1A1LMNA | |
| SCHEMBL15383959 | 0.80 | PER2 (1.00) | PER2CRY1CRY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180071306-A1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. | 2018-03-15 | — | — | US | claimed |
| US-10383880-B2 | Carbazole-containing sulfonamides as cryptochrome modulators | Synchronicity (US) | 2019-08-20 | — | — | US | disclosed |
| EP-2855458-B1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | RESET THERAPEUTICS INC (US) | 2018-08-08 | — | — | EP | disclosed |
| US-20180071306-A1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. | 2018-03-15 | — | — | US | disclosed |
| US-20180071306-A1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. | 2018-03-15 | — | — | US | disclosed |
| US-9775845-B2 | Carbazole-containing sulfonamides as cryptochrome modulators | RESET THERAPEUTICS, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9775845-B2 | Carbazole-containing sulfonamides as cryptochrome modulators | RESET THERAPEUTICS, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9775845-B2 | Carbazole-containing sulfonamides as cryptochrome modulators | RESET THERAPEUTICS, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20160200732-A1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. | 2016-07-14 | — | — | US | disclosed |
| US-20160200732-A1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. | 2016-07-14 | — | — | US | disclosed |
| US-20160200732-A1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. | 2016-07-14 | — | — | US | disclosed |
| US-9265772-B2 | Carbazole-containing sulfonamides as cryptochrome modulators | RESET THERAPEUTICS, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9265772-B2 | Carbazole-containing sulfonamides as cryptochrome modulators | RESET THERAPEUTICS, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20130303524-A1 | Carbazole-Containing Sulfonamides as Cryptochrome Modulators | Synchronicity Pharma, Inc. | 2013-11-14 | — | — | US | disclosed |
| US-20130303524-A1 | Carbazole-Containing Sulfonamides as Cryptochrome Modulators | Synchronicity Pharma, Inc. | 2013-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303524-A1 | Carbazole-Containing Sulfonamides as Cryptochrome Modulators | CRY1, CRY2, CRYAB | PER2 183/4885CRY1 1/4885CRY2 2/4885 |
| US-20160200732-A1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | CRY1, CRY2, CRYAB | PER2 155/4885CRY1 1/4885CRY2 2/4885 |
| US-10383880-B2 | Carbazole-containing sulfonamides as cryptochrome modulators | CRY1, CRY2, CRYAB | PER2 155/4885CRY1 1/4885CRY2 2/4885 |
| US-20180071306-A1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | CRY1, CRY2, CRYAB | PER2 155/4885CRY1 1/4885CRY2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.